Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial.
Publication
, Journal Article
Wanner, C; Cooper, ME; Johansen, OE; Toto, R; Rosenstock, J; McGuire, DK; Kahn, SE; Pfarr, E; Schnaidt, S; von Eynatten, M; George, JT ...
Published in: Clinical kidney journal
September 2021
[This corrects the article DOI: 10.1093/ckj/sfaa225.].
Duke Scholars
Published In
Clinical kidney journal
DOI
EISSN
2048-8513
ISSN
2048-8505
Publication Date
September 2021
Volume
14
Issue
9
Start / End Page
2136
Related Subject Headings
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Wanner, C., Cooper, M. E., Johansen, O. E., Toto, R., Rosenstock, J., McGuire, D. K., … Perkovic, V. (2021). Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial. Clinical Kidney Journal, 14(9), 2136. https://doi.org/10.1093/ckj/sfab104
Wanner, Christoph, Mark E. Cooper, Odd Erik Johansen, Robert Toto, Julio Rosenstock, Darren K. McGuire, Steven E. Kahn, et al. “Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial.” Clinical Kidney Journal 14, no. 9 (September 2021): 2136. https://doi.org/10.1093/ckj/sfab104.
Wanner C, Cooper ME, Johansen OE, Toto R, Rosenstock J, McGuire DK, et al. Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial. Clinical kidney journal. 2021 Sep;14(9):2136.
Wanner, Christoph, et al. “Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial.” Clinical Kidney Journal, vol. 14, no. 9, Sept. 2021, p. 2136. Epmc, doi:10.1093/ckj/sfab104.
Wanner C, Cooper ME, Johansen OE, Toto R, Rosenstock J, McGuire DK, Kahn SE, Pfarr E, Schnaidt S, von Eynatten M, George JT, Gollop ND, Marx N, Alexander JH, Zinman B, Perkovic V. Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial. Clinical kidney journal. 2021 Sep;14(9):2136.
Published In
Clinical kidney journal
DOI
EISSN
2048-8513
ISSN
2048-8505
Publication Date
September 2021
Volume
14
Issue
9
Start / End Page
2136
Related Subject Headings
- 3202 Clinical sciences